Table 2.

Mean frequencies of unique HVR1 nucleotide sequences for each patient subpopulation



Mean complexity
Time point
Progressors (n = 10)
Nonprogressors (n = 10)
Difference: progressor-nonprogressor
Coinfected (n = 16)    
    Early   0.78 (SE, 0.02)   0.54 (SE, 0.09)   0.24  
    Late   0.65 (SE, 0.07)   0.72 (SE, 0.07)   -0.07  
Monoinfected (n = 4)    
    Early   0.53 (SE, 0.03)   0.81 (SE, 0.18)   -0.28  
    Late   0.48 (SE, 0.23)   1.0 (SE, 0.0)   -0.52  
Total    
    Early   0.73 (SE, 0.04)   0.59 (SE, 0.08)   0.14  
    Late   0.61 (SE, 0.04)   0.77 (SE, 0.07)   -0.16  
        Late-early
 
-0.12 (SE, 0.07)
 
0.18 (SE, 0.10)
 
-0.30*
 


Mean complexity
Time point
Progressors (n = 10)
Nonprogressors (n = 10)
Difference: progressor-nonprogressor
Coinfected (n = 16)    
    Early   0.78 (SE, 0.02)   0.54 (SE, 0.09)   0.24  
    Late   0.65 (SE, 0.07)   0.72 (SE, 0.07)   -0.07  
Monoinfected (n = 4)    
    Early   0.53 (SE, 0.03)   0.81 (SE, 0.18)   -0.28  
    Late   0.48 (SE, 0.23)   1.0 (SE, 0.0)   -0.52  
Total    
    Early   0.73 (SE, 0.04)   0.59 (SE, 0.08)   0.14  
    Late   0.61 (SE, 0.04)   0.77 (SE, 0.07)   -0.16  
        Late-early
 
-0.12 (SE, 0.07)
 
0.18 (SE, 0.10)
 
-0.30*
 

Frequencies were determined by the proportion of unique nucleotide sequences to the number of clones assessed for each patient at early and late time points.

*

P = .01 for difference in unique nucleotide sequence frequencies between progressors and nonprogressors over time (generalized estimating equation model with binomial distribution and logit link).